Oppenheimer Holdings Inc. initiated coverage on shares of TESARO Inc (NASDAQ:TSRO) in a report released on Thursday. The firm set an “outperform” rating and a $183.00 price target on the biopharmaceutical company’s stock. Oppenheimer Holdings Inc.’s price target indicates a potential upside of 17.51% from the stock’s previous close.

Several other analysts have also recently issued reports on the stock. Cann assumed coverage on shares of TESARO in a research report on Wednesday. They set an “outperform” rating on the stock. Jefferies Group LLC restated a “hold” rating on shares of TESARO in a research report on Wednesday, May 10th. Cowen and Company restated a “hold” rating and set a $145.00 target price on shares of TESARO in a research report on Thursday, May 11th. FBR & Co decreased their target price on shares of TESARO from $202.00 to $200.00 and set a “mkt perform” rating on the stock in a research report on Wednesday, May 10th. Finally, Citigroup Inc reissued a “buy” rating and issued a $216.00 price objective (down from $232.00) on shares of TESARO in a research report on Saturday, April 22nd. Seven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $172.86.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

TESARO (NASDAQ:TSRO) opened at 155.73 on Thursday. The company’s market capitalization is $8.39 billion. The firm’s 50-day moving average price is $144.83 and its 200 day moving average price is $150.05. TESARO has a one year low of $36.71 and a one year high of $192.94.

TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.26) by $0.29. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative net margin of 798.68% and a negative return on equity of 141.88%. The firm’s quarterly revenue was up 909.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($2.22) earnings per share. On average, equities research analysts expect that TESARO will post ($8.72) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/25/tesaro-inc-tsro-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc.html.

In other TESARO news, COO Mary Lynne Hedley sold 3,927 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total value of $697,474.47. Following the completion of the sale, the chief operating officer now directly owns 10,000 shares in the company, valued at $1,776,100. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Grant C. Bogle sold 1,447 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $177.61, for a total transaction of $257,001.67. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,432 shares of company stock valued at $2,902,602. 40.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of TSRO. Putnam Investments LLC boosted its position in TESARO by 0.4% in the fourth quarter. Putnam Investments LLC now owns 10,429 shares of the biopharmaceutical company’s stock worth $1,402,000 after buying an additional 46 shares in the last quarter. Teacher Retirement System of Texas boosted its position in TESARO by 2.1% in the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 60 shares in the last quarter. Profund Advisors LLC boosted its position in TESARO by 3.8% in the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock worth $394,000 after buying an additional 93 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in TESARO by 0.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock worth $2,576,000 after buying an additional 150 shares in the last quarter. Finally, Stephens Inc. AR boosted its position in TESARO by 11.0% in the first quarter. Stephens Inc. AR now owns 1,759 shares of the biopharmaceutical company’s stock worth $271,000 after buying an additional 175 shares in the last quarter. 98.48% of the stock is owned by institutional investors and hedge funds.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

12 Month Chart for NASDAQ:TSRO

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.